Recent Finacing
Recent Raise
Amunix Pharmaceuticals develops masked, protease-activated prodrugs—XPAT T cell engagers and XPAC cytokines—using XTEN/Pro‑XTEN technologies to enable tumor‑microenvironment–selective activation and reduced toxicity.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Amunix.
